1. Home
  2. FSLR vs DGX Comparison

FSLR vs DGX Comparison

Compare FSLR & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Solar Inc.

FSLR

First Solar Inc.

HOLD

Current Price

$238.99

Market Cap

22.8B

Sector

Technology

ML Signal

HOLD

Logo Quest Diagnostics Incorporated

DGX

Quest Diagnostics Incorporated

HOLD

Current Price

$236.59

Market Cap

23.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FSLR
DGX
Founded
1999
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.8B
23.2B
IPO Year
2006
1996

Fundamental Metrics

Financial Performance
Metric
FSLR
DGX
Price
$238.99
$236.59
Analyst Decision
Buy
Buy
Analyst Count
27
13
Target Price
$236.42
$214.38
AVG Volume (30 Days)
2.0M
1.0M
Earning Date
04-30-2026
04-21-2026
Dividend Yield
N/A
1.82%
EPS Growth
18.22
13.78
EPS
7.14
5.08
Revenue
$5,219,376,000.00
$11,035,000,000.00
Revenue This Year
$1.43
$7.53
Revenue Next Year
$16.77
$3.77
P/E Ratio
$34.12
$46.01
Revenue Growth
24.09
11.78
52 Week Low
$176.47
$171.18
52 Week High
$320.95
$240.13

Technical Indicators

Market Signals
Indicator
FSLR
DGX
Relative Strength Index (RSI) 57.21 72.51
Support Level $217.35 $189.62
Resistance Level $248.93 $240.13
Average True Range (ATR) 10.42 6.36
MACD 5.10 1.08
Stochastic Oscillator 70.29 87.87

Price Performance

Historical Comparison
FSLR
DGX

About FSLR First Solar Inc.

First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.

About DGX Quest Diagnostics Incorporated

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Share on Social Networks: